(I) Construction project name: Construction project of Minhai Biological New Vaccine International Industrial Base (Phase I)
(2) Location: Daxing Biomedical Industrial Base, Daxing District, Zhongguancun Science and Technology Park, Daxing District, Beijing, 053-039, 040, 043, 044, east to Tianfu Street, south to the planned land boundary, west to Xiangrui Street, north to Si Miao Road.
(3) Construction content: The project uses a scale of 90013.218m2, above-ground building scale of 135020m2; floor area ratio of 1.5; building density of 40%; green space ratio of 15%; controlled height of 36 meters. Annual production of 20 million doses of combined cell-free leukoplakia inactivated poliomyelitis and Haemophilus influenzae type b vaccine; 25 million doses of pneumococcal conjugate vaccine; Mabella varicella series vaccine: Mabira combined attenuated live vaccine Agent, 5 million doses of attenuated live attenuated varicella and chickenpox vaccine, and 10 million doses of lyophilized live attenuated varicella vaccine.
(4) Name of construction unit: Beijing Minhai Biological Technology Co., Ltd.
Contact: Xia Zhanxiong
(5) Compiling unit of environmental impact report: Puhua Holdings Co., Ltd.
(6) Web link for public comment form: http://www.biominhai.com/xwzx_xi/newsId=347.html
(7) Ways and means of submitting public comment forms.
In the process of preparing the draft of the environmental impact report, the public can submit opinions related to the environmental impact assessment to the construction unit.